Combining aripiprazole and haloperidol presents a clinical and pharmacological puzzle. On one hand, you have haloperidol, a potent D₂ antagonist that fully blocks dopamine; on the other, aripiprazole, a partial agonist with high affinity that displaces the antagonist only to provide a weaker signal. This interplay can be dangerous, potentially triggering a "dopamine supersensitivity psychosis" in a brain already adapted to chronic blockade, leading to a sudden worsening of symptoms. Yet, this same mechanism can be harnessed to treat stubborn side effects like hyperprolactinemia, making it a tempting strategy. In this episode of PsyQ, we dissect the competing pharmacology, review the conflicting case literature—from successful augmentation to severe relapse—and provide evidence-based, practical guidance on how to navigate this combination. Join us for a deep dive into this double-edged sword of psychopharmacology, equipping you with the knowledge to proceed with caution and confidence.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit upathak.substack.com